FDA Adverse Event Injury Summary report: N

AXERA ACCESS SYSTEM

MDR report key: 2251368 · Received September 13, 2011

Report

Report Number
3008493244-2011-00032
Event Type
Injury
Date Received
September 13, 2011
Date of Event
August 8, 2011
Report Date
August 16, 2011
Manufacturer
ARSTASIS INC.
Product Code
DYB
PMA / PMN Number
K103143
Adverse Event
Yes
Report Source
Manufacturer report
Reporter Location
FL, US
Reporter Occupation
PHYSICIAN

Narratives

Additional Manufacturer Narrative · 1

THE DEVICE WAS NOT RETURNED; THEREFORE, FAILURE ANALYSIS COULD NOT BE PERFORMED. A REVIEW OF THE DEVICE HISTORY RECORD AND COMPLAINT HISTORY FOR THIS LOT WAS NOT PERFORMED AS THE LOT NUMBER WAS NOT REPORTED. HOWEVER, NON CONFORMING MATERIALS REPORT (NCMR) HISTORY FROM THE LAST 6 MONTHS WAS REVIEWED AND NO NCMRS HAVE BEEN INITIATED THAT ARE RELATED TO THIS FAILURE MODE. THE INSTRUCTIONS FOR USE WAS REVIEWED AND PSEUDOANEURYSM IS LISTED AS A POSSIBLE COMPLICATION. BASED ON AVAILABLE INFORMATION, THERE IS NO INDICATION THAT THE IFU WAS NOT FOLLOWED. BASED ON THE ANALYSIS COMPLETE, THERE IS NO EVIDENCE TO SUFFEST THE DEVICE WAS OUT OF SPECIFICATION. THE PROBABLE ROOT CAUSE OF THE REPORTED PSEUDOANEURYSM IS UNKNOWN.

Description of Event or Problem · 1

THE PHYSICIAN PERFORMED A DIAGNOSTIC INDEX PROCEDURE THROUGH THE COMMON FEMORAL ARTERY OF AN AVERAGE SIZE MALE PATIENT. THE PROCEDURE WAS UNREMARKABLE WITH NO TORTUOSITY OR CALCIFICATION OF THE VESSEL, AND THE ACCESS SITE OF THE AXERA DEVICE WAS REPORTED TO BE CORRECT. THE EVENING AFTER THE PROCEDURE A RE-BLEED AT THE ACCESS SITE WAS REPORTED, AND A SECOND RE-BLEED WAS REPORTED 7.5 HOURS LATER IN THE MORNING. BY MID-AFTERNOON THE SUBJECT HAD A SCAN AND IT WAS DETERMINED THAT THERE WAS A PSEUDOANEURYSM NEAR THE ACCESS SITE. THE PSEUDOANEURYSM WAS TREATED WITH A THROMBIN INJECTION. THE PATIENT WAS OK AT DISCHARGE WHICH OCCURRED 2 TO 3 DAYS AFTER THE INDEX PROCEDURE.

Devices

Seq Brand Generic Product Code Manufacturer Model Lot UDI-DI
1 AXERA ACCESS SYSTEM INTRODUCER CATHETER DYB ARSTASIS INC.

Patients

Seq Age Sex Outcome Treatment
1 Required Intervention